Trial · NCT04501861
Hemodynamic Effect of Norepinephrine Versus Vasopressin on the Pulmonary Circulation in Cardiac Surgery Patients:
NCT04501861, Phase 3, Completed, The Cleveland Clinic; results first posted 2025-01-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Hemodynamic Effect of Norepinephrine Versus Vasopressin on the Pulmonary Circulation in Cardiac Surgery Patients:. Trials, record NCT04501861. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04501861
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hemodynamic Effect of Norepinephrine Versus Vasopressin on the Pulmonary Circulation in Cardiac Surgery Patients:
- NCT number
- NCT04501861
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 153 participants, actual
- Lead sponsor
- The Cleveland Clinic
- Conditions
- Cardiac Disease
- Interventions
- Vasopressin, Norepinephrine
- First posted
- 2020-08-06
- Last updated
- 2026-10-27
- Results first posted
- 2025-01-09
- Limitations and caveats
Our study protocol excluded patients at particularly high risk for acute right ventricular failure. Thus, our conclusions should not be extrapolated to such vulnerable populations. Our analysis was not adequately powered to evaluate mortality and other major clinical outcomes.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | mPAP-to-MAP Ratio | during 20 minute period after chest closure | The intraoperative mean pulmonary artery pressure(mPAP) adjusted for systemic mean arterial pressure(MAP), using a time-weighted average mPAP-to-MAP ratio measured during 20 minute period after chest closure |
| Secondary | RV Free Wall Strain | during 20 minutes period after chest closure | Right Ventricular Free Wall Longitudinal Strain (RV FWLS) is a measure of the deformation (strain) of the right ventricle's free wall (the part not attached to the septum) during contraction. It quantifies how much the myocardium in the free wall of the right ventricle shortens along its longitudinal axis (base to apex) during systole (contraction). It is expressed as a negative percentage (%), where more negative values indicate better contractility (e.g., -20% is better than -10%). In this study, it was measured by transesophageal echocardiography in the 2D mid-esophageal four-chamber view during a steady state period after chest closure |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | mPAP-to-MAP Ratio | during 20 minute period after chest closure | Not all the patients in the 2 groups with preoperative pulmonary arterial hypertension, we only included the eligible patients. | ratio of mPAP-to-MAP | MEAN |
| SECONDARY | RV Free Wall Strain | during 20 minutes period after chest closure | Included all patients for RV free wall strain. As not all the patients with/without preoperative pulmonary arterial hypertension, so the study pop in subgroup are different. | percentage of RV free wall strain | MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| mPAP-to-MAP Ratio | The Use of Vasopressin | mPAP-to-MAP ratio | 0.394 | Standard Deviation 0.086 | ratio of mPAP-to-MAP |
| mPAP-to-MAP Ratio | The Use of Norepinephrine | mPAP-to-MAP ratio | 0.385 | Standard Deviation 0.094 | ratio of mPAP-to-MAP |
| mPAP-to-MAP Ratio | The Use of Vasopressin | mPAP-to-MAP ratio with preop pulmonary hypertension | 0.42 | Standard Deviation 0.082 | ratio of mPAP-to-MAP |
| mPAP-to-MAP Ratio | The Use of Norepinephrine | mPAP-to-MAP ratio with preop pulmonary hypertension | 0.40 | Standard Deviation 0.093 | ratio of mPAP-to-MAP |
| mPAP-to-MAP Ratio | The Use of Vasopressin | mPAP-to-MAP ratio without preop pulmonary hypertension | 0.37 | Standard Deviation 0.084 | ratio of mPAP-to-MAP |
| mPAP-to-MAP Ratio | The Use of Norepinephrine | mPAP-to-MAP ratio without preop pulmonary hypertension | 0.36 | Standard Deviation 0.092 | ratio of mPAP-to-MAP |
| RV Free Wall Strain | The Use of Vasopressin | RV free wall strain | -18.2 | Standard Deviation 8.4 | percentage of RV free wall strain |
| RV Free Wall Strain | The Use of Norepinephrine | RV free wall strain | -19.4 | Standard Deviation 7.2 | percentage of RV free wall strain |
| RV Free Wall Strain | The Use of Vasopressin | RV free wall strain with preop pulmonary hypertension | -17.5 | Standard Deviation 8.4 | percentage of RV free wall strain |
| RV Free Wall Strain | The Use of Norepinephrine | RV free wall strain with preop pulmonary hypertension | -18.9 | Standard Deviation 8.1 | percentage of RV free wall strain |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | The Use of Vasopressin | 70 | |
| Overall Study | STARTED | The Use of Norepinephrine | 83 | |
| Overall Study | COMPLETED | The Use of Vasopressin | 0 | |
| Overall Study | COMPLETED | The Use of Norepinephrine | 0 | |
| Overall Study | NOT COMPLETED | The Use of Vasopressin | 70 | |
| Overall Study | NOT COMPLETED | The Use of Norepinephrine | 83 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | The Use of Vasopressin | 0 | 0 |
| Total, all-cause mortality | The Use of Norepinephrine | 0 | 0 |
| Total, other adverse events | The Use of Vasopressin | 0 | 0 |
| Total, other adverse events | The Use of Norepinephrine | 0 | 0 |
| Total, serious adverse events | The Use of Vasopressin | 0 | 0 |
| Total, serious adverse events | The Use of Norepinephrine | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04501861
GET https://conductscience.org/api/trials/v1/NCT04501861/registered